Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
The healthcare industry can make for a safe place to invest regardless of the macroeconomic conditions. A couple of healthcare stocks that are diversified and that could be good buys heading into the new year are AstraZeneca (NASDAQ: AZN) and PetMed Express (NASDAQ: PETS). AstraZeneca's business performed well in 2022, but its stock isn't doing as well as perhaps it should be.
Shares of Compugen (NASDAQ: CGEN), a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday. The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01, before jumping to $1.23 in the late afternoon and closing at $1.20. The stock has been volatile, with a 52-week low of $0.51 and a 52-week high of $4.88.